Abingdon will use the money to buy 50.1% of Molecular Vision, another Imperial Innovations portfolio company, as well as for other projects, including those from its Bioscience Ventures joint venture with the University of Birmingham.
Imperial Innovations Group, a UK-listed university venturing firm spun out from Imperial College, London, has invested two-thirds of a £3m ($4.7m) round for Abingdon Health, a local medical diagnostics company, to help it buy a peer. Abingdon will buy 50.1% of Molecular Vision, another Imperial Innovations portfolio company, as well as use the money for…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
